Carmona-Rocha, E.; Rusiñol, L.; Puig, L. New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics2024, 16, 239.
Carmona-Rocha, E.; Rusiñol, L.; Puig, L. New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics 2024, 16, 239.
Carmona-Rocha, E.; Rusiñol, L.; Puig, L. New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics2024, 16, 239.
Carmona-Rocha, E.; Rusiñol, L.; Puig, L. New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics 2024, 16, 239.
Abstract
The introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current research is focused on development of oral therapies with improved efficacy and safety compared to available alternatives, as exemplified by deucravacitinib, the first oral allosteric Tyk2 inhibitor approved for the treatment of moderate-to-severe psoriasis in adults. Recent advances in our knowledge of psoriasis pathogenesis have also led to the development of targeted topical molecules, mostly focused on intracellular signaling pathways, such as AhR, PDE-4 and Jak-STAT. Topical tapinarof, an AhR modulator, and roflumilast, a PDE-4 inhibitor, have exhibited favorable efficacy and safety outcomes have been approved by the FDA for the topical treatment of plaque psoriasis. This revision focuses on the most recent oral and topical therapies available for psoriasis and specially on those that are currently under evaluation and development for the treatment of psoriasis.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
